Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 20;40(5):397–405. doi: 10.1007/s40266-023-01023-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

PMC Copyright notice

Fig. 5 — Synergistic and deleterious effects of PARPi and aging on the HSC pool, lymphopoiesis and apoptosis pathway in HSC leading to lymphopenia. Schematic evolution of lymphocyte count in older patients: age-related hematopoietic changes lead to lymphocyte count decrease (1), initiation of PARPi treatment might escalate this decrease (2), which can be further worsened by other intercurrent events (3), possibly leading to lymphopenia-related complications. PARPi poly(ADP-ribose) polymerase inhibitors, HSC hematopoietic stem cell, BM bone marrow